Search

Displaying results 7871 - 7880 of 9692 in total
  1. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  2. Drug

    Elsibucol

    go.drugbank.com/drugs/DB05840
    Experimental

    AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common

  3. Drug

    AI-850

    go.drugbank.com/drugs/DB05842
    Experimental

    AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.

  4. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  5. Drug

    CPD 923

    go.drugbank.com/drugs/DB05856
    Experimental

    It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

  6. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  7. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets. … PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme.

  8. Drug

    AVI-4020

    go.drugbank.com/drugs/DB05873
    Investigational

    AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).

  9. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  10. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    CHF 4227 is a new selective estrogen receptor modulator (SERM). … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis.